During this “Ask the Expert” webinar, Dr. Kerry Rogers answered audience questions about chronic lymphocytic leukemia (CLL), helping patients and their loved ones better understand the disease, explore treatment options, and gain tools for navigating care.
Dr. Kerry Rogers is a hematologist-oncologist and Associate Profesor at The Ohio State University Comprehensive Cancer Center – The James.
Related Resources
Transcript
Katherine Banwell:
Hello and welcome. Thank you for joining us for the Patient Empowerment Network’s live “Ask the CLL Expert” program, the first in its Connect series. I’m Katherine Banwell.
Today’s webinar is all about your questions, and here to provide expert answers is Dr. Kerry Rogers. Dr. Rogers, welcome. Would you please introduce yourself?
Dr. Kerry Rogers:
Hi. I’m Kerry Rogers. I’m a hematologist, and I work at the Ohio State University in Columbus, Ohio.
Katherine Banwell:
We’re so glad you’re joining us today. Thank you. Before we get started, let’s quickly review a few housekeeping items. First, we have received a number of questions for Dr. Rogers. We will get to as many as we can. You can submit questions yourself during the webinar via the Q&A box on your Zoom screen.
As you are sending in questions, please remember that we cannot answer specific questions about your medical treatment. Those should be discussed with your own healthcare team.
You will also receive a survey immediately following the program. Please share your experience with us so that we can hear that we’re doing well, and what we are doing well, and continue to improve our programming. All right. Let’s get to the Q&A. Dr. Rogers, let’s start with this first one from Mary. She asks, “In what way is AI helping CLL patients?”
Dr. Kerry Rogers:
I think this is a really excellent question, and there are several ways that AI is helping CLL patients. When I think about AI, I think about that being artificial intelligence, and there are a few different ways it’s used. One way that’s helped a lot, at least in my clinic, is patients educating themselves about CLL using AI. So, I think we all realize that AI is probably not the right place to get specific medical advice on what treatment’s best for you, etc.
But it is actually a pretty good way to learn about CLL in a way that you can relate to. Everyone learns from a different background, and I found that a variety of AIs have really helped my patients learn about their condition so that they could ask better questions. So, I feel sometimes I have a more engaging conversation with someone who has had a chat with AI before coming to my clinic, and also has had an AI help them generate questions to ask, so then they can go through and have all them at the end.
And sometimes I say, “Do you want those answered first? Or do you want me to talk?” And then we’ll answer them. And so, I feel like maybe people get more out of their visits if they’ve talked to ChatGPT or Claude or Gemini or a different AI program before coming to see me.
Katherine Banwell:
Yeah. Yeah.
Dr. Kerry Rogers:
So, again, this is not the AI picking treatment, but just the education.
Katherine Banwell:
Absolutely. Yeah, that’s great advice.
Dr. Kerry Rogers:
I was going to add on the other side, then the research front, I do think it will benefit CLL patients.
I know some of my colleagues want to do some really deep science, single-cell sequencing, and it’s really helped him do more with his data sets and process them more. So, it’s probably not something that helps people directly in clinic yet, but I do think some of the data organization and research applications of AI will help people with CLL.
Katherine Banwell:
Yeah. Okay, good point. The next question is from Ralph: “There are currently no available measles vaccines for immunocompromised people. What can we do to speed up development for a vax?”
Dr. Kerry Rogers:
Yeah. That’s a great question. So, that is true. The current highly effective measles vaccine is the MMR, and that is a live vaccine. So, that is not suitable for people with CLL due to the risk that the live vaccine itself will cause an infection. The good news is people born before a certain year, and I can never remember exactly what year that is, aren’t at risk for measles because they were either exposed to it or presumed immune to it. And a lot of people are vaccinated as a child, as I was, in which case you don’t have to worry too much because that is a good amount of protection.
So, there aren’t current recommendations to revaccinate people who have received measles vaccines, say, before they got CLL or who were born before a certain year. In terms of development of new vaccines, I think that takes a lot of scientific effort. There are many approaches to making vaccines these days, but the type of vaccine that’s made also depends on the type of immune response you want to generate against the virus. So, I’m not really sure how feasible it will be to use some of the technologies, like mRNA technologies that were used for COVID vaccines. I don’t know that will translate to measles directly.
I think if you personally are invested in that research happening, you can ask organizations that do vaccine research to do this or to try to support it. I actually don’t do that kind of vaccine research, but you can again use AI to find out who does that kind of research and write them an email saying you’re interested in this.
And I think if enough people do, that certainly could result in the change or, of course, coming together as a group and lobbying for your interest in having an effective vaccine.
Katherine Banwell:
Yeah. Okay. Thanks for that, Dr. Rogers. This next question comes from Betsy. She’d like to know how diet affects or doesn’t affect the progression of CLL.
Dr. Kerry Rogers:
This is a really good question that I get asked all the time. Currently, we do not have any evidence for any particular diet making CLL better or worse. This kind of research on diet is extremely hard to do because, as you know, people eat a variety of things from different backgrounds; things they like to eat, things they grew up eating. And then to try to track what people were eating or how their diet affects how they’re doing is also really hard because you have to log what you’re eating. Different foods in different areas, even though they’re the same type of food, can be different.
So, it’s very hard to do this type of research on diet, and then to try to tell people to eat differently for a period of time is also really challenging. As you can imagine, there are things people like to eat. There is starting to become some evidence in other blood cancers, like multiple myeloma, that a plant-based diet – so, maybe not strict vegan, but that’s what we’re talking about; we’re talking about a diet that does not have meats and dairy and eggs in it, improved outcomes for slower growing or less aggressive forms of blood cancer called multiple myeloma.
So, there was some evidence that controlling the diet did actually change the cancer in that case. Now, we don’t know that that’s true for CLL, but I would really like to study that and find out. And I think that’s a really important question that should be answered with the same kind of diet interventions that they used in the multiple myeloma study. Additionally, I do think that there is a lot of evidence that eating a well-balanced diet – so, I think someone put it to me like this once, “Eat real foods and not too much, mostly plants.”
And that kind of dietary advice that really goes back decades seems to really be good advice today, and every time we ask the question again, that’s what people say. And as people with CLL live a very long time with their disease in most cases, it’s really important to make sure you eat really well for things like your cardiovascular health too. So, I do think that a healthy diet improves your body in more ways than just effect on the CLL. I know that’s really important for people living with a chronic cancer like CLL where they expect to be around a long time.
So, I hope that in the future I’m able to say more about what specific diets improve CLL. Right now, my guess would be it’s going to be a plant-based diet, but I do hope to find out in the next few years as we do more research in that area.
Katherine Banwell:
What about exercise? That must be good. Yes?
Dr. Kerry Rogers:
Yeah.
Katherine Banwell:
Usually it is for most people.
Dr. Kerry Rogers:
Yes, I think so too. I can think of very few things that exercise is not good for, right? You have to stretch your brain to think of something exercise isn’t good for.
Every time I see a study on exercise, it ends up looking better and better. I don’t know of any exercise prescription that directly reduces white blood cell count or reduces amount of CLL. But again, across multiple measures, exercise is good for people and certainly improves things you would expect to improve CLL outcomes, like lean body mass and blood sugar control. The crazy thing about exercise, and people always look at me like I’m out of my mind when I say this, is that moderate exercise improves fatigue.
People with CLL live with fatigue quite a bit, and frequently it’s like a low-level fatigue that I really can’t do much to improve. Of course, a lot of fatigue from CLL improves with CLL treatment, but exercise has been shown to improve fatigue, even moderate exercise several times a week. So, I do think that is one way that CLL patients living with fatigue specifically also could address that. People think I’m a little crazy when they’re like, “I’m tired,” and I’m telling you to go exercise, but it does tend to work.
Katherine Banwell:
Yeah, I’ve heard that too.
Dr. Kerry Rogers:
Yeah.
Katherine Banwell:
Let’s get to our next question. Allen would like to know, “When is a bone marrow biopsy needed?”
Dr. Kerry Rogers:
Hmm. I think that’s a really good question too. We just have a whole list of great questions today. So, the good news for people with CLL is that a bone marrow biopsy is not needed for the diagnosis; that is made based on a blood test. So, I say a bone marrow biopsy should be done anytime you need to learn something from it.
So, the most common reason we do them is when people have anemia, which is a low hemoglobin, or thrombocytopenia, which is low platelets, and we really need to know, “Is that from the CLL? Or is something else going on?” Especially if we’re going to treat the CLL due to low blood counts, it really makes sense to do a bone marrow biopsy so that we’re 100 percent sure that these low blood counts are from the CLL and will get better with CLL treatment.
I think it’s important just to have that reassurance in those cases. They’re also used quite frequently for clinical trials to assess response. I think when you’re studying a new treatment or an established treatment, it’s important to do the bone marrow biopsy to see how well that worked. So, the two places it’s really useful are for diagnosis of, “Is the CLL causing low blood counts?” and then for clinical trial outcomes.
Katherine Banwell:
Dr. Rogers, let’s take this question next about medication used to treat CLL. Kim asks, “How common now is the acalabrutinib (Calquence) and venetoclax (Venclexta) treatment regimen? What is the newest information on this form of treatment?
Dr. Kerry Rogers:
That is an excellent question about a newer treatment. So, as most people may or may not know, there are two major strategies for treating CLL as a first treatment these days are, either a class of drugs called BTK inhibitors, which includes the original one, ibrutinib, which is marketed under the brand name Imbruvica, and that’s not used as much anymore.
The two that have a safer cardiovascular profile, Calquence, which is acalabrutinib, or Brukinsa, which is zanubrutinib. And those are given as a single medication long-term, so, for years. And the other strategy is to use a drug called venetoclax, which really decreases the amount of CLL in the body quickly. And venetoclax is combined with either an antibody called obinutuzumab (Gazyva) or a BTK inhibitor.
So, it’s been studied with both ibrutinib (Imbruvica) and acalabrutinib, which is what’s being asked about here, that’s Calquence. And so, these are given actually for a duration of a little over a year. So, this is a new strategy. I would say that the acalabrutinib, or Calquence, and venetoclax treatment is increasing in popularity. One reason for this is that a lot of people like the, “One year, and then I end treatment and go about my business without treatment strategy,” and I can see why that’s appealing.
The prior option for that was to get venetoclax with infusions. And for anyone that’s familiar with venetoclax, it has about a five-week, visit-intensive startup scheme. When you start adding infusions to that, it’s a lot of work. Infusions can have scary reactions. So, this kind of scheme is two pills. So, Calquence or acalabrutinib, which is a pill, and then venetoclax, and so, it’s an easier way to do a one-year treatment. This got FDA-approved for the treatment of CLL.
And I think because of the convenience factor, it’s used very commonly because it’s still kind of a short-term treatment, but it’s a little less work to take, and pills are easier than infusions. The outcomes are very good. We don’t have a head-to-head with this acalabrutinib-venetoclax, and these other treatments yet. We do have a ibrutinib-venetoclax head-to-head with venetoclax-obinutuzumab – head-to-head with ibrutinib.
And again, we don’t use ibrutinib really in the U.S. anymore because of the heart-related risks. But this one had the same BTK inhibitor and compared these strategies, and at three years, the percent of people in remission was actually the same. I think if you go out to six years, we’re going to see better results with the long-term strategy, but that’s also a long-term dosing scheme. But it does seem to be very effective. I think we’re going to get a lot more information with it as people are using it more.
But I would say the convenience and the fixed-duration scheme have made this very popular, and it should be used for a lot of patients. Some people with high-risk CLL, such as deletion 17P CLL, choose to take the long-term treatment because the outcomes are a little better, remissions are longer, for high-risk CLL. But for others, this two-agent pill choice is a really nice option.
Katherine Banwell:
Okay. Thank you for that. This next question comes from Mark: “Is ‘watch and wait’ always the best path for a Rai stage I patient?”
Dr. Kerry Rogers:
Hmm. That’s an excellent question. So, “observation,” or “watch-and-wait,” or some people call it “surveillance,” just means that because you have CLL doesn’t mean it has to be treated right away. So, there are randomized studies going back to some reported, when I was in high school, that randomized people. So, it’s a clinical trial that assigned people with intermediate or high-risk CLL to either treatment at diagnosis or treatment in the future when you needed it, and there was no difference in survival or how long people lived. And they repeated some of that.
The German CLL study group did a study called CLL-12 that was ibrutinib at diagnosis or placebo compared to treatment when you needed it and got the same result. So, that’s with the modern therapy, and there was no improvement in survival. So, we know that early treatment doesn’t help people live any longer. However, the only reason to treat CLL is not always the Rai stage.
So, Rai stage I CLL would be CLL where there are lymph nodes that people can feel. Sometimes having lymph nodes enlarge really quickly, even if it’s still Rai stage I, is a reason for treatment. I’ve had a few patients where even though they weren’t large enough to be medically bothersome, it was very bothersome to the person and interfering with their life to have the lymph nodes, especially on their neck. That is a reason for treatment; if someone who’s living with CLL it really is bothered by the lymph nodes.
And then the other reason for treatment for Rai stage I CLL would be symptoms like fatigue. So, these are symptoms from hormones released from CLL cells, which are immune system cells, and that can make people feel really bad. I’ve had people that had to quit their hobbies. I had someone that was too tired to get off their floor and go to work, and that’s not okay, and treatment will improve that.
So, even if the fatigue does not go in Rai staging, it has to do with whether or not you have low blood counts from CLL, whether or not your lymph nodes are enlarged, etc. And so, even if you have Rai stage I CLL, if you have something like fatigue or if the lymph nodes that may get Rai stage I are really ruining your life, then treatment would be better than observation.
Katherine Banwell:
Yeah, that makes sense.
Dr. Kerry Rogers:
Yeah.
Katherine Banwell:
David sent us this question: “How common –“ actually, it’s a scenario for him: “How common is this? Ibrutinib stops working after four years. Patient stops treatment. WBC drops one-half. Next, more ‘watch and wait?’ And if so, for how long?”
Dr. Kerry Rogers:
Yeah. So, this is a very interesting scenario. It’s hard to know without some of the specifics by what “ibrutinib stops working” means. I do have a few things to say that might help us understand this better. One is, BTK inhibitors, like ibrutinib, that’s also acalabrutinib and zanubrutinib, block a cell-signaling pathway called B-cell receptor signaling by blocking BTK, which is in that pathway.
When that B-cell receptor signaling is blocked, the CLL cells will leave the lymph nodes, the tissue, and go into the blood. So, for anyone that’s taken one of these drugs, right within days of taking it, sometimes within hours of taking it, you see the white blood cell count get really high because all the CLL cells go into the blood. When people stop taking it, same thing happens in reverse, so, you can actually see the residual CLL cells home back to the tissues. So, you can see someone that has like, “Oh. They still have lymphocytes in the blood on ibrutinib, and then they quit taking it, and it’ll potentially drop by half just because those cells are there, they just go back into the tissues.”
So, it’s not completely surprising that the lymphocytes or white blood cell dropped by half when a BTK inhibitor was stopped. I don’t know what it means by “not working.” So, if something like lymph nodes had increased or there was some really bad symptom when the CLL came back while they were taking it, then probably they would need treatment for that.
However, I have had people stop ibrutinib for various reasons. And if they stop it and there’s no reason to treat the CLL, then, yes, they should go on observation until there’s something that is improved by treatment. And I have had patients stop BTK inhibitors, mostly when they are in remission, but after long-term use, and stay in remission for years.
So, I would say to anyone who stopped a BTK inhibitor for whatever reason, if everything looks great, they should have a talk with their doctor about observation and not just another other treatment, and see what their doctor’s thinking if treatment’s recommended right away, because many patients can go on observation for a time.
Katherine Banwell:
Well, the next question is related. Leslie would like to know, “What is the relationship between BTK inhibitors and anemia?”
Dr. Kerry Rogers:
Oh. So, BTK inhibitors work on B cells. They actually work both on CLL cells, which are kind of a cancer arising from B cells and healthy B cells. They don’t have many known direct effects on the bone marrow cells are erythroid precursors that make red blood cells.
So, anemia is low levels of red blood cells. But there are several ways in which BTK inhibitors can cause anemia. So, in many cases, they improve anemia. So, if you have low red blood cells because you have too much CLL cells in the marrow, the BTK inhibitor is going to fix that, and your anemia will improve.
However, people can develop anemia on BTK inhibitors in the first four weeks to a month or two on BTK inhibitors. Sometimes as the bone marrow clears out the CLL, you will see platelets, hemoglobin, you will see anemia occur at the beginning and then start to improve. I don’t know exactly why that happens. I think it’s kind of a bone marrow healing process, or at least that’s how I think about it. And then, one way unrelated to its effect on the bone marrow, BTK inhibitors can cause anemia through increasing bleeding.
So, BTK inhibitors have an effect on blood platelets, which are blood-clotting cells, and they don’t always drop the number of platelets, but they make them work less well, kind of like aspirin does. And I’ve seen many times that someone had bleeding from somewhere, especially like GI bleeding, bleeding into their gastrointestinal tract, that they couldn’t see. So, it’s not that they saw blood in their stool or knew they were bleeding, and then, they start taking a BTK inhibitor, and whatever blood vessel malformation or irritation or whatever was bleeding in the GI tract, when you stop the platelets from working as well, it starts bleeding a lot more.
So, you can end up seeing anemia occur because this bleeding that wasn’t really noticeable, it now becomes noticeable. And the way to address that isn’t really stopping the BTK inhibitor because they’re still going to have the problem that was bleeding in the first place. It’s really doing the diagnostic test to figure out, “Is something bleeding? Does it need treatment?” I’ve had people that had something called a hiatal hernia that had irritated their stomach that was bleeding and actually got that fixed and was even better off than before this happened.
So, that is one way in which BTK inhibitors can cause anemia. So, hopefully it’s not straightforward. There’s not one relationship between BTK inhibitors and anemia. There can be multiple ways those can interact.
Katherine Banwell:
Yeah, it sounds like it. The next question comes from Michelle: “Are stem cell transplants curative for CLL and for Richter’s transformation? And if so, are they safe?”
Dr. Kerry Rogers:
So, the first answer to the first two questions, the answer is yes. So, a donor stem cell transplant – so, there’s more than one type of stem cell transplant in the world; we’re talking about a donor stem cell transplant, absolutely can cure CLL and Richter’s transformation, which is an aggressive lymphoma in someone with CLL. These are procedures where you get high-dose chemotherapy to allow your body to accept a donor immune system and then get an infusion of blood stem cells from a donor, which could be a relative or could be someone you don’t know.
And then over a period of about a month, or even more, actually, these donor immune cells engraft in your body, and then they actually take over your blood production. And the reason you want this is that you want that donor’s immune system to attack your cancer. That’s the whole goal. So, it’s not to just replace your bone marrow; it’s actually to have an immune system in your body from someone else that’s going to fight your cancer.
So, that does have this prospect of, what I would consider, a cure, which would be living your entire life dying of something else and never having the CLL come back. That can happen. The problem is, that doesn’t happen very often, or it’s not very effective. So, it’s less than half the patients. The number that’s usually quoted is about a third that are alive and with their CLL cured. Some people actually can die from infections during that process.
And then the real problem is that donor immune system that you want to attack the CLL cells can actually attack your cells, like your skin or the line of your intestines or your lungs. It’s called graft-versus-host disease, and it is very serious. And while we have gotten better at managing that, CLL patients seem to have very high rates of graft-versus-host disease, maybe because their own immune system wasn’t normal before they got the donor immune system. So, stem cell transplant can absolutely be used for people who need it, but for the majority of patients, the cure is worse than the disease, if you know what I mean.
This is not a safe and effective treatment for most patients. And getting a donor stem cell transplant does come with a lifelong need to meet with transplant doctors, take medications, and actually the medical care burden of this is extremely high. So, the answer is, yes, that that can be curative.
We do use it in Richter’s quite a bit because Richter’s is not something people tend to live with long term. It either needs to be cured or, unfortunately, people die of it. So, it is used there more. We try not to use it a lot in CLL. So, it can be helpful when you really need it, but it’s not for most people.
And I think the second part of that question, which is, “Is it safe?” The answer is, not really. So, it is something that can be done when needed, and sometimes it is the right thing to do, but it is not what you think of as a safe treatment compared to all the other pills and options we have. And actually, CAR T is much safer than a donor stem cell transplant. So, hopefully that clarified. It’s a really cool technology. It’s helped a lot of people. But in CLL, it’s not something that we need to do often. And we have much better options for people, even though they’re not curative.
Katherine Banwell:
Well, it’s good to know, though.
Dr. Kerry Rogers:
Yep.
Katherine Banwell:
William wants to know, “Given the typical degradation of a CLL patient’s immune function, if there are any specific research or trials to address this impact?”
Dr. Kerry Rogers:
There is a lot of research. I would like to say we had a treatment that worked for this, but not currently. There’s one thing we can do to help. So, the immune system is kind of like an orchestra. Hopefully everyone’s had the opportunity to see a symphony orchestra at some point. I grew up in Chicago, so we used to go to the Chicago Symphony Orchestra. And actually, my maternal aunt that I had, used to play contrabassoon with them quite a bit. But as you know, if you got to the orchestra, there are all these sections together, right? So, there are the woodwinds and multiple types of woodwinds. There’s types of strings. There’s a ton of weird percussion instruments, and they all come together to do the symphony.
The immune system’s like that too. So, there are antibodies and B cells and T cells and something called natural killer cells. There are actually subsets of natural killer cells. And then actually just the barrier for skin is technically part of your immune system.
So, all these things work in concert. And I think the current problem is we can address like one of those aspects of those things, but we can’t really make them all play music well together again. And so, making this work out globally is not something within our present capabilities. Maybe with AI research we’ll get there, but I don’t see that on the horizon just yet.
The one or two things that we do know can help: So, there’s immunoglobulin replacement. Sometimes the immunoglobulin, which is a fancy word for antibody, levels get low over the course of having CLL. Many CLL treatments tend to lower them further, but CLL itself lowers antibodies or immunoglobulins. For people with low immunoglobulins that get a lot of infections, there is immunoglobulin replacement. So, that is either IV or subcutaneous, which is like an injection treatment of donor antibodies, so, antibodies from blood donors, much safer than grafting a donor immune system. So, these are just antibody proteins that wear off, kind of like your natural proteins do.
So, just an ongoing, usually monthly, treatment if it’s given IV, and that can really help people. So, that’d be kind of like the woodwind section getting taken out and then brought in replacements for the woodwind. So, that can help if the woodwinds are the problem. I will say some people do great with low antibody levels and don’t get injections. So, in those cases, we say maybe this particular composition didn’t need woodwinds; it’s going fine. So, that’s one way.
But we don’t have something to restore the global health of the immune system yet. I do think that there’s some research that maybe having a – so, when we used to give chemotherapy that ended, and was like a fixed duration and ended, that is very destructive to immune systems. We think that some of these things like the acalabrutinib-venetoclax, or venetoclax-obinutuzumab, if the CLL is in remission and people are off treatment, that might help the immune system a little, but we don’t know yet. And it’s certainly not a fix-all.
So, I would say that the immunoglobulin replacement is just one thing we can do. We don’t have a lot else. And then, personally, I recommend people with CLL get all the vaccines they’re due for. They don’t get as much benefit from the vaccines just because the immune system is not normal, but they still get some. And we’re actually studying repeat dosing of the pneumococcal pneumonia vaccine to see if we can improve the immune response to that. So, I think there’s also a lot of hope for some of those supportive care things that might help people live better, even if their immune system’s out of tune, so to speak.
Katherine Banwell:
Yeah. Aviva K. would like to know, “Does Calquence work for as long as I live?”
Dr. Kerry Rogers:
Oh, that’s a good question. I have no idea, because I don’t know how long you’re going to live, right? So, Calquence, which is acalabrutinib, does work for many years. And so, we don’t know actually, if it’s taken as a first treatment, with the median or if you can think of that as an average amount of time it works for.
We only know that for ibrutinib, and it’s 8.9 years. So, that means with ibrutinib, if it’s taken as a first treatment, if you look at a group of people taking it, at 8.9 years, half of them are still alive and in remission. So, that’s pretty good. So, I would expect that acalabrutinib or Calquence would work for many years. Most of the time, it’s more than five years, but, again, everyone’s different for how long it will work for them specifically. That’s as a first treatment. If someone’s had multiple other treatments, usually it worked for more like three years on average.
And then the other thing I just really don’t know is how long this person’s going to live because that’s not up to us, right? So, I have people that ask me, “Oh, do I have to take acalabrutinib for the rest of my life?” and I said, “I have no idea. It depends on how long you live. If you get hit by a bus next week, no. If you live another two decades, it probably won’t work that long, and we’ll come up with something else.” So, that’s a tough one. I do think, though, the reality is for people who are in their late 80s or 90s, most people that I’ve spoken to in their 90s don’t expect to live another 10 years – not that they couldn’t, but most people don’t think that way when they are in their 90s.
And so, then for many of them, the acalabrutinib or BTK inhibitor will work for the rest of their natural lifespan, and they’ll die of something else before the drug stops working. So, that is something that’s true for a lot of patients. We also did see in a pooled analysis of clinical trials with ibrutinib – because that’s the first BTK inhibitor we have the most data with, even though we don’t use it really anymore – that people who took that as a first treatment had normal survival compared to age-matched controls.
So, that’s people of the same age and sex that didn’t have CLL, and the amount of them that were alive at follow-up were the same as the population. So, it’s kind of saying that people aren’t really dying of CLL, but I don’t know if that meant that the ibrutinib worked for the rest of their life. And most of them were actually still alive at the end of the study. So, that’s a TBD on that.
Katherine Banwell:
Well, thank you to everyone who sent in questions for our program today. As we wrap up the webinar, let’s hear some closing thoughts from Dr. Rogers. What would you like to leave to audience with?
Dr. Kerry Rogers:
So, I think that one of the things about living with CLL is that most people are happy and healthy and get to live with it for a long time. And while it certainly has an impact on people’s overall health, most of the people get to do what they want. So, people living with CLL should plan for things in the future, should plan to do things they enjoy doing, and I’d really recommend that everyone continue to educate themselves on it and to keep asking questions. I’m probably preaching to the choir, talking to people that are watching this program.
But I think it’s really important to learn about your health in any way you can so that you can continue to ask your doctors really good questions so that you get the most out of your visits, and that you get the most out of your healthcare and get what you need addressed, and to not be afraid to bring up things that are affecting your life and happiness in terms of your health.
Because I think it’s really important, and as I was saying at the beginning, people are starting to use AI to educate themselves so they can ask better questions of their doctors, and I think that’s wonderful.
Katherine Banwell:
Thanks for joining us today, Dr. Rogers. It was a pleasure talking to you.
Dr. Kerry Rogers:
Yeah, same.
Katherine Banwell:
And thank you to all of our collaborators. To learn more about CLL and to access tools to help you become a proactive patient, visit powerfulpatients.org. I’m Katherine Banwell. Thank you so much for joining us.